Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.4%

4 terminated/withdrawn out of 90 trials

Success Rate

92.5%

+6.0% vs industry average

Late-Stage Pipeline

11%

10 trials in Phase 3/4

Results Transparency

10%

5 of 49 completed trials have results

Key Signals

13 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

26(37.7%)

N/A

24(34.8%)

Phase 1

9(13.0%)

Phase 4

7(10.1%)

Phase 3

3(4.3%)

69Total

Phase 2(26)

N/A(24)

Phase 1(9)

Phase 4(7)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (90)

Showing 20 of 90 trials

NCT03767530Not ApplicableRecruiting

Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction

Role: collaborator

NCT03655912Not ApplicableRecruiting

Binocular Visual Therapy and Video Games for Amblyopia Treatment.

Role: collaborator

NCT03653650Not ApplicableRecruiting

Autologous Platelet-rich Plasma in the Treatment of Persistent Epithelial Defects

Role: collaborator

NCT04604834Not ApplicableRecruiting

Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy

Role: collaborator

NCT07451652Phase 2Recruiting

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Role: lead

NCT07497555Not ApplicableRecruiting

Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Randomized Controlled Parallel-Group Clinical Trial

Role: collaborator

NCT06209190Not ApplicableCompleted

Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation

Role: lead

NCT07401992Phase 4Recruiting

Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

Role: lead

NCT07319000Phase 2Completed

Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT

Role: lead

NCT07039877Phase 2Recruiting

Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients

Role: lead

NCT01740869Phase 3Completed

Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders

Role: lead

NCT06904599Phase 2Recruiting

Efficacy of Human Chorionic Gonadotropin in Acute GVHD Treatment

Role: lead

NCT06892119Phase 1Completed

Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation

Role: lead

NCT06886074Phase 2Recruiting

Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

Role: lead

NCT06758375Phase 2Recruiting

Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

Role: lead

NCT02820051Not ApplicableCompleted

Non-anesthesiologist-administered Propofol During the Flexible Bronchoscopy

Role: lead

NCT06676709Phase 1Completed

Effect of IMMUNEPOTENT-CRP on Serum Pro-Inflammatory Cytokines in Mild to Moderate COVID-19

Role: collaborator

NCT06348602Phase 1Recruiting

Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT

Role: lead

NCT06273020Phase 4Recruiting

Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke

Role: lead

NCT05772624Phase 2Unknown

Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

Role: lead